<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01497327</url>
  </required_header>
  <id_info>
    <org_study_id>P2938-0515</org_study_id>
    <nct_id>NCT01497327</nct_id>
  </id_info>
  <brief_title>Open-Label Hepatic Impairment Study</brief_title>
  <official_title>An Open-Label Study to Characterize the Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of PSI-7977 or PSI-352938 in HCV-infected Subjects With Varying Degrees of Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted in Hepatitis C positive patients to determine whether the
      pharmacodynamic effects of PSI-7977 or PSI-352938 are similar to HCV-infected patients with
      normal hepatic function, which may allow inclusion of patients with cirrhosis and varying
      degrees of hepatic dysfunction in future clinical studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed per the Food and Drug Administration (FDA) guidance for patients with
      impaired hepatic function to assess the influence of hepatic impairment on the PK and
      pharmacodynamics (PD) of PSI-7977 and PSI-352938 This study will be conducted in Hepatitis C
      positive patients to ascertain whether the PD effects of PSI-7977 or PSI-352938 are similar
      to HCV-infected patients with normal hepatic function, which may allow inclusion of patients
      with cirrhosis and varying degrees of hepatic dysfunction in future clinical studies. Data
      from subjects who participated in the P2938-0212 study (PSI-352938 MAD) will be used as the
      control group. These subjects were documented non-cirrhotic subjects with normal hepatic
      function. Hepatitis C Virus (HCV) Genotypes 1-6 will be enrolled in this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic data derived from plasma samples collected over 7 days</measure>
    <time_frame>28 time points over Seven Days</time_frame>
    <description>To characterize the pharmacokinetics (PK) of PSI-352938 over 7 days of dosing with PSI-352938 in HCV-infected patients with varying degrees of hepatic impairment compared to historical PK data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic comparison with historical data over 7 days of dosing with PSI-7977</measure>
    <time_frame>Seven Days</time_frame>
    <description>To characterize the PK of PSI-7977 and metabolites over 7 days of dosing with PSI-7977 in HCV-infected patients with varying degrees of hepatic impairment compared to historical PK data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and severity of adverse events</measure>
    <time_frame>Seven Days</time_frame>
    <description>To assess the safety and tolerability of 7 days of dosing of PSI-352938 or PSI-7977 in HCV infected patients with varying degrees of hepatic impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral dynamics/ changes in HCV (ribonucleic acid) RNA</measure>
    <time_frame>Baseline through follow-up (post-Day 14)</time_frame>
    <description>To evaluate the viral dynamics as measured by changes in the HCV RNA in HCV-infected patients with varying degrees of hepatic impairment after 7 days of dosing with PSI-352938 or PSI-7977.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in genotypic or phenotypic measurements</measure>
    <time_frame>Seven Days</time_frame>
    <description>To assess the presence of baseline polymorphisms in viral isolates and development of viral genotypic and phenotypic changes from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage adjustment in hepatically impaired patients</measure>
    <time_frame>Seven days</time_frame>
    <description>To provide dosage adjustment guidance for PSI-352938 or PSI-7977 based on the degree of hepatic impairment, if applicable.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>PSI-352938 Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild (Child-Pugh Class A; 5-6) hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PSI-352938 Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate (Child-Pugh Class B; 7-9) hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PSI-352938 Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe (Child-Pugh Class C; 10-15) hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PSI-7977 Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild (Child-Pugh Class A; 5-6) hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PSI-7977 Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate (Child-Pugh Class B; 7-9) hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PSI-7977 Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe (Child-Pugh Class C; 10-15) hepatic impairment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PSI-352938</intervention_name>
    <description>PSI-352938 300mg once daily (QD) for seven days</description>
    <arm_group_label>PSI-352938 Group A</arm_group_label>
    <arm_group_label>PSI-352938 Group B</arm_group_label>
    <arm_group_label>PSI-352938 Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PSI-7977</intervention_name>
    <description>PSI-7977 400mg QD for seven days</description>
    <arm_group_label>PSI-7977 Group A</arm_group_label>
    <arm_group_label>PSI-7977 Group B</arm_group_label>
    <arm_group_label>PSI-7977 Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hepatic impaired Males or females of non-childbearing potential aged &gt; 18 years with
             Chronic HCV-infection

          -  Na√Øve to all direct acting anti-viral (DAA) treatments for chronic HCV infection.

          -  Documented Cirrhosis

        Exclusion Criteria:

          -  Prior PEG/RBV null responders.

          -  Unstable cardiac disease, recent Myocardial infarction, or family history of QTc
             prolongation or unexplained cardiac arrest.

          -  Positive test at Screening for anti-HAV IgM Ab, HBsAg, anti-HBc IgM Ab, or anti-human
             immunodeficiency virus (HIV) Ab.

          -  History of clinically significant medical condition associated with other chronic
             liver disease

          -  Any current signs or symptoms of severe hepatic encephalopathy

          -  History of gastric or esophageal variceal bleeding in which varices have not been
             adequately treated with medication and surgical procedures

          -  Prior placement of a portosystemic shunt

          -  History of hepatorenal, or hepatopulmonary syndrome.

          -  Active spontaneous bacterial peritonitis.

          -  Use of medications associated with QT prolongation within 28 days prior to dosing.

          -  Current Hypotension

          -  History of Torsades de Pointes, evidence of an active or suspected cancer, or a
             history of malignancy, Abnormal hematological and biochemical parameters
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2011</study_first_submitted>
  <study_first_submitted_qc>December 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2011</study_first_posted>
  <last_update_submitted>June 7, 2012</last_update_submitted>
  <last_update_submitted_qc>June 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HEPATITIS C, CHRONIC</keyword>
  <keyword>HCV</keyword>
  <keyword>hepatic impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

